Tartaglia J, Cox W I, Pincus S, Paoletti E
Virogenetics Corporation, Rensselaer Technology Park, Troy, NY.
Dev Biol Stand. 1994;82:125-9.
NYVAC-based recombinants expressing pertinent immunogens from equine influenza virus (EIV), pseudorabies virus (PRV), Japanese encephalitis virus (JEV) and human immunodeficiency virus (HIV) were used to evaluate the safety and immunogenicity of this vector. Administration of either NYVAC recombinants or parenteral virus to mice, horses and swine was well tolerated with no notable local or systemic reactivities. Further, despite a highly attenuated phenotype, NYVAC was found to function effectively as an immunization vehicle capable of eliciting both humoral and cell-mediated immune responses.
基于NYVAC的重组体表达了来自马流感病毒（EIV）、伪狂犬病病毒（PRV）、日本脑炎病毒（JEV）和人类免疫缺陷病毒（HIV）的相关免疫原，用于评估该载体的安全性和免疫原性。将NYVAC重组体或亲本病毒给予小鼠、马和猪，耐受性良好，没有明显的局部或全身反应。此外，尽管NYVAC具有高度减毒的表型，但它被发现能有效地作为一种免疫载体，引发体液免疫和细胞介导的免疫反应。
